Thomas Winder
Overview
Explore the profile of Thomas Winder including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
85
Citations
1820
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stintzing S, Klein-Scory S, Fischer von Weikersthal L, Fuchs M, Kaiser F, Heinrich K, et al.
J Clin Oncol
. 2025 Feb;
:JCO2401174.
PMID: 39903881
Purpose: The FIRE-4 study randomly assigned patients with first-line wild-type (wt) metastatic colorectal cancer to either flourouracil (FU), folinic acid, and irinotecan (FOLFIRI) plus cetuximab until progression or intolerable toxicity...
2.
Reimann P, Mavroeidi I, Burghofer J, Taghizadeh H, Webersinke G, Kasper S, et al.
Cancer Immunol Immunother
. 2024 Oct;
73(12):251.
PMID: 39358611
Introduction: This study assesses the effectiveness of durvalumab with platinum and gemcitabine for biliary tract cancers (BTC). It aims to confirm the TOPAZ-1 trial results in a real-world context and...
3.
Mark M, Mora A, Winder T, Stathis A, Jakob A, Muller G, et al.
Bone Rep
. 2024 Aug;
22:101794.
PMID: 39139592
Background: Patients with bone metastases from solid tumors often have additional treatment with bone targeted agents (BTAs) to avoid symptomatic skeletal events (SSEs) such as clinically significant pathological fracture leading...
4.
Reimann P, Petzer V, Mundlein A, Hartmann B, Severgnini L, Winkler A, et al.
Ann Hematol
. 2024 Mar;
103(6):2123-2131.
PMID: 38436671
Monoclonal antibodies, as tixagevimab/cilgavimab, have been introduced as prophylaxis against COVID-19 infections in high-risk populations. However, data on efficacy are limited. This study investigates efficacy and tolerability of tixagevimab/cilgavimab in...
5.
Kafka M, Giannini G, Artamonova N, Neuwirt H, Ofner H, Kramer G, et al.
Clin Genitourin Cancer
. 2024 Jan;
22(2):458-466.e1.
PMID: 38267304
Introduction: Two randomized trials demonstrated a survival benefit of triplet therapy (androgen deprivation therapy [ADT]) plus androgen receptor pathway inhibitor [ARPI] plus docetaxel) over doublet therapy (ADT plus docetaxel), thus...
6.
Barth D, Moik F, Steinlechner S, Posch F, Mayer M, Sandner A, et al.
J Immunother Cancer
. 2023 Dec;
11(12).
PMID: 38097343
Background: C reactive protein (CRP) kinetics have recently been suggested as predictive biomarkers for the efficacy of immune checkpoint inhibitor (ICI) therapy in selected cancer types. The aim of this...
7.
Heymach J, Harpole D, Mitsudomi T, Taube J, Galffy G, Hochmair M, et al.
N Engl J Med
. 2023 Oct;
389(18):1672-1684.
PMID: 37870974
Background: Neoadjuvant or adjuvant immunotherapy can improve outcomes in patients with resectable non-small-cell lung cancer (NSCLC). Perioperative regimens may combine benefits of both to improve long-term outcomes. Methods: We randomly...
8.
Taghizadeh H, Djanani A, Eisterer W, Gerger A, Gruenberger B, Gruenberger T, et al.
Front Oncol
. 2023 Sep;
13:1225154.
PMID: 37711201
Locally advanced or metastatic cholangiocarcinoma is an aggressive carcinoma with a dismal prognosis. For the first-line treatment of locally advanced or metastatic cholangiocarcinoma, cisplatin/gemcitabine has been the standard of care...
9.
Woll E, Amann A, Eisterer W, Gerger A, Grunberger B, Rumpold H, et al.
Anticancer Res
. 2023 Jun;
43(7):2889-2897.
PMID: 37351962
Over the last decade, therapeutic options for patients with gastric cancer have improved significantly. However, despite these recent advances, mortality is still substantial. Surgery and chemotherapy represent the cornerstones of...
10.
Stiefel R, Lehmann K, Winder T, Siebenhuner A
BMC Cancer
. 2023 Feb;
23(1):148.
PMID: 36782152
Background: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a heterogeneous group of tumors with a broad range of local and systemic treatment options. Still a lack of data regarding treatment sequences exists....